Skip to main content
Clinical Trials/NCT06285357
NCT06285357RecruitingNot Applicable

A Pilot Study to Test the Effect of the Association of Epigallocatechin Gallate (EGCG), Folic Acid and Vitamin B12 in Preventing the Persistence of Human Papilloma Virus (HPV) Infection.

Lo.Li.Pharma s.r.l2 sites in 1 country100 target enrollmentStarted: February 19, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
100
Locations
2
Primary Endpoint
HPV DNA test negativity

Study Overview

Brief Summary

The purpose of the study is to test the effect of the administration of a dietary supplement consisting of epigallocatechin gallate (EGCG), vitamin B12 and folic acid in the treatment of infections with papilloma virus of the cervix.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
25 Years to 65 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • HR-HPV DNA test positivity

Exclusion Criteria

  • Not provided

Arms & Interventions

control

No Intervention

treatment

Experimental

Intervention: EGCG + folic acid + B12 (Dietary Supplement)

Outcomes

Primary Outcomes

HPV DNA test negativity

Time Frame: 8 months of treatment

Percentage

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials